Biocon Revenue History — Quarter by Quarter

Biocon's revenue moved from ₹3,516 Cr in Q1 FY24 to ₹4,517 Cr in Q4 FY26, a 28.5% change over 12 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q4 FY26	₹4,517 Cr	+10%
Q3 FY26	₹4,173 Cr	+9%
Q2 FY26	₹4,296 Cr	+20%
Q1 FY26	₹3,942 Cr	+15%
Q4 FY25	₹4,417 Cr	+15%
Q3 FY25	₹3,821 Cr	+10%
Q2 FY25	₹3,590 Cr	+8%
Q1 FY25	₹3,433 Cr	0%
Q4 FY24	₹3,917 Cr	+4%
Q3 FY24	₹3,954 Cr	+34%
Q2 FY24	₹3,462 Cr	+49%
Q1 FY24	₹3,516 Cr	+59%

What management said about revenue

Q4 FY26 · Biosimilar revenue growth of 16% in FY26 on like-to-like basis

Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.

Q4 FY26 · Aflibercept (Yesafili) launch in US in H2 FY27

Settlement with originator allows entry; management expects meaningful revenue contribution from H2.

Q2 FY26 · Biosimilar R&D spend at 7-9% of revenue

Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.

Q2 FY26 · Generics R&D spend at 8-10% of revenue

Generics R&D spend is expected to be in the 8-10% range of segment revenue.

Q2 FY26 · Syngene maintains FY26 annual guidance

Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.

Q1 FY26 · Generics double-digit revenue growth for FY26

Management expects strong double-digit revenue growth for the generics segment for the full fiscal year, driven by multiple product launches including liraglutide in Europe and the U.S.

Q1 FY26 · Liraglutide U.S. approval expected this fiscal

Liraglutide U.S. file is under FDA review with a target action date; approval and launch expected during FY26.

Q1 FY26 · Denosumab U.S. approval by end of calendar 2025

Biocon Biologics expects U.S. FDA approval for denosumab before the end of calendar 2025.

Q1 FY26 · Semaglutide filings in Q2 FY26 for emerging markets and Canada

Semaglutide will be filed in Q2 FY26 in many emerging markets and Canada, with best-case approval by end of calendar 2026.

Q4 FY25 · Five biosimilar launches in 12-18 months

Management expects to launch Yesintek (launched), Bevacizumab, Aspart, Aflibercept (US H2 2026), and Denosumab within the next 12-18 months.

Q4 FY25 · Liraglutide US approval expected in H2 CY2025

Target action date in H2 2025; facility cleared, queries responded; ready to launch immediately upon approval.

Q3 FY25 · Biosimilar Ustekinumab launch in February 2025

Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.